Nova Eye Medical Limited (ASX: EYE) - Share Price
Current share price for EYE : $0.110 0.005 (4.35%)+
Nova Eye Medical Limited (EYE), an ASX-listed company, is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons globally, these technologies include iTrack and Molteno3. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of distribution partners. Manufacturing facilities are in Fremont, California and Dunedin, New Zealand.
EYE General Information +
| ASX Code | EYE |
| Website | N/A |
| Industry/Sector | Health Care Equipment |
| Market Cap ($M) | 31 |
| EYE Share Price | $0.110 |
| Day High | $0.110 |
| Day Low | $0.110 |
| Last Close | $0.115 |
| EYE Share Price Movement | $0.01 ( 4.35% ) |
Prices as at 16:40, 15 Jul 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Nova Eye Medical Limited (EYE) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|---|---|---|---|---|---|---|
| SpecialEvent | 29¢ | 0% | 21 Jul 2020 | 29 Jul 2020 | - | - | - |
See all dividends from Nova Eye Medical Limited (EYE) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Nova Eye Medical Limited (EYE) price-sensitive announcements
EYE - EYE lifts Sales Guidance
Nova Eye Medical Limited has reported a record monthly sales figure in the USA for April 2
Nova Eye Medical Limited (EYE)
5 May 2026 | 9:48 AM
5 May 2026 | 9:48 AM
EYE - Quarterly Activities/Appendix 4C Cash Flow Report
Nova Eye Medical Limited reported a strong quarter ending 31 March 2026, with sales increa
Nova Eye Medical Limited (EYE)
29 Apr 2026 | 8:26 AM
29 Apr 2026 | 8:26 AM
EYE - EYE Delivers Sales Growth and Improves Bottom Line
Nova Eye Medical Limited reported significant sales growth and improvements in their finan
Nova Eye Medical Limited (EYE)
26 Feb 2026 | 8:16 AM
26 Feb 2026 | 8:16 AM
EYE - Half Yearly Report and Accounts
Nova Eye Medical Limited's half-year report ending 31 December 2025 indicates a significan
Nova Eye Medical Limited (EYE)
26 Feb 2026 | 8:15 AM
26 Feb 2026 | 8:15 AM
Nova Eye Medical Limited (EYE) Recent ASX Announcements
EYE Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | -$9.06 | -$3.70 | -15.10% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$8.79 | -$4.30 | -25.30% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$9.25 | -$5.80 | 14.30% | 0.00 | 0.00 | 0.00% | 0.0% |
EYE Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| Cochlear Limited (COH) | $7,933M | 0.0171 | -0.1883 | 0.0862 | 20.2697 | 24.9717 | 22.9909 | 3.54% | 2.86% | 3.05% |
| Nova Eye Medical Limited (EYE) | $33M | -0.1508 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Fisher & Paykel Healthcare Corporation Limited (FPH) | $19,469M | 0.1388 | 0.1334 | 0.1883 | 50.1285 | 44.2295 | 37.2221 | 1.31% | 1.40% | 1.58% |
| ResMed Inc. (RMD) | $16,971M | 0.3087 | 9.7669 | 0.0811 | 196.4924 | 18.2498 | 16.8804 | 1.17% | 1.23% | 1.30% |
EYE Directors
| Name | Position | Start Date |
|---|---|---|
| Mr Mike Southard | Executive Director | 2 Jul 2018 |
| Mr Victor Previn | Executive Director, Executive Chairman | 16 Jul 2001 |
| Mr Thomas (Tom) Anthony Spurling | Managing Director | 29 Aug 2020 |
| Mr Rahmon Coupe | Non-Executive Director | 15 May 2013 |
| Mr Daniel Webb | Non-Executive Director | 17 Nov 2022 |
Nova Eye Medical Limited (EYE) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 1 Sep 2025 | SPURLING, Thomas (Tom) | Buy | Direct Shares | 78,273 | $0.150 | $11,740.950 |
| 26 Mar 2025 | WEBB, Daniel | Issued | Indirect Shares | 416,666 | $0.120 | $49,999.920 |
| 26 Mar 2025 | SPURLING, Thomas (Tom) | Issued | Indirect Shares | 166,666 | $0.120 | $19,992.920 |
See all changes in directors' interest & trades for Nova Eye Medical Limited (EYE) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
EYE Management
| Name | Position |
|---|---|
| Simon Ramsey Alexander Gray | Company Secretary |
EYE Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Nova Eye Medical Limited (EYE). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 52,624,920 (18.48%) | HSBC Custody Nominees (Australia) Limited |
EYE Calendar of Events
| Date | Event |
|---|---|
| 25 February 2027 | Report (Interim) |
| 26 August 2026 | Report (Annual) |
| 26 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
